Navigation Links
NBTY Reports First Quarter Results

BOHEMIA, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- NBTY, Inc. (NYSE: NTY) (, a leading global manufacturer and marketer of nutritional supplements, today announced results for the fiscal first quarter ended December 31, 2007.

For the fiscal first quarter ended December 31, 2007, net sales were $511 million compared to $506 million for the fiscal first quarter ended December 31, 2006, an increase of $5 million or 1%.

Net income for the fiscal first quarter ended December 31, 2007 was $46 million, or $0.67 per diluted share, compared to $51 million, or $0.73 per diluted share, for the fiscal first quarter ended December 31, 2006. This reflects the decrease in earnings in the Direct Response/E-Commerce division.

Adjusted EBITDA for the fiscal first quarter of 2008 was $87 million. At December 31, 2007, NBTY had total assets of $1.6 billion and working capital of $603 million, of which $236 million consisted of cash and short-term investments. The Company is committed to using its cash and leverage to increase shareholder value through opportunistic acquisitions and stock repurchases.

In October 2007, NBTY purchased in open market transactions 296 thousand shares of its common stock for approximately $11 million dollars. These shares were purchased under an existing publicly announced authorization. NBTY anticipates continuing such purchases on an opportunistic basis. Based on market conditions, these repurchases may be greater than historical repurchases.


Net sales for the Wholesale/US Nutrition division, which markets Nature's Bounty, Solgar, Osteo Bi-Flex, Rexall, Ester-C ADJUSTED EBITDA**

Reconciliation of GAAP Measures to Non-GAAP Measures


(In thousands)


DECEMBER 31, 2007

Pretax Depreciation

Income and Non-cash Adjusted

(Loss) amortization Interest charges EBITDA**

Wholesale /

US Nutrition $53,981 $2,694 $- $- $56,675

North American Retail (864) 850 350 336

European Retail 35,067 3,063 38,130

Direct Response /

E-Commerce 7,123 1,366 8,489

Segment Results 95,307 7,973 - 350 103,630

Corporate /

Manufacturing (26,047) 5,959 3,862 - (16,226)

Total $69,260 $13,932 $3,862 $350 $87,404


DECEMBER 31, 2006

Pretax Depreciation

Income and Non-cash Adjusted

(Loss) amortization Interest charges EBITDA**

Wholesale /

US Nutrition $49,589 $2,789 $- $- $52,378

North American Retail 1,087 1,137 - 353 2,577

European Retail 38,824 2,828 - - 41,652

Direct Response /

E-Commerce 15,593 1,265 - - 16,858

Segment Results 105,093 8,019 - 353 113,465

Corporate /

Manufacturing (28,329) 6,212 5,063 - (17,054)

Total $76,764 $14,231 $5,063 $353 $96,411









NBTY, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets


(Dollars and shares in thousands,

except per share amounts)

December 31, September 30,

2007 2007

Current assets:

Cash and cash equivalents $98,941 $92,902

Investments 137,301 121,382

Accounts receivable, net 111,226 98,454

Inventories 390,321 384,990

Deferred income taxes 21,856 21,441

Prepaid expenses and other current assets 52,825 54,460

Total current assets 812,470 773,629

Property, plant and equipment, net 323,193 323,154

Goodwill 248,614 251,753

Intangible assets, net 159,045 157,548

Other assets 29,386 28,851

Total assets $1,572,708 $1,534,935

Current liabilities:

Current portion of long-term debt $1,008 $989

Accounts payable 72,931 71,852

Accrued expenses and other

current liabilities 135,658 125,533

Total current liabilities 209,597 198,374

Long-term debt, net of current portion 209,400 210,106

Deferred income taxes 58,272 61,788

Other liabilities 11,586 8,697

Total liabilities 488,855 478,965

Commitments and contingencies

Stockholders' equity:

Common stock, $0.008 par; authorized

175,000 shares; issued and outstanding

66,822 shares at December 31, 2007 and

67,118 shares at September 30, 2007 535 537

Capital in excess of par 142,864 143,244

Retained earnings 897,516 864,852

Accumulated other comprehensive income 42,938 47,337

Total stockholders' equity 1,083,853 1,055,970

Total liabilities and stockholders' equity $1,572,708 $1,534,935

NBTY, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows


(In thousands)

For the three months

ended December 31,

2007 2006

Cash flows from operating activities:

Net income $45,822 $50,856

Adjustments to reconcile net

income to cash and cash equivalents

provided by operating activities:

Impairments and disposals of

property, plant and equipment 462 392

Depreciation and amortization 13,932 14,231

Foreign currency transaction (gain) loss (1,299) 318

Amortization and write-off of deferred charges 152 1,303

Amortization of bond discount 34 31

Allowance for doubtful accounts (229) (135)

Inventory reserves 1,061 2,292

Deferred income taxes 449 3,886

Excess income tax benefit from

exercise of stock options (88) (20)

Changes in operating assets and

liabilities, net of acquisitions:

Accounts receivable (11,789) (2,516)

Inventories (7,784) (5,087)

Prepaid expenses and other current assets 1,275 4,443

Other assets (490) (163)

Accounts payable 687 2,834

Accrued expenses and other liabilities 7,842 10,241

Net cash provided by operating activities 50,037 82,906

Cash flows from investing activities:

Purchase of property, plant and equipment (9,814) (6,212)

Purchase of available-for-sale investments (55,148) (214,718)

Proceeds from sale of available-for-sale

investments 39,272 154,844

Cash paid for acquisitions,

net of cash acquired (5,072) (38,219)

Cash collateral securing loan - (18,360)

Net cash used in investing activities (30,762) (122,665)

Cash flows from financing activities:

Principal payments under long-term

debt agreements and capital leases (239) (196)

Payments for financing fees - (1,649)

Excess income tax benefit

from exercise of stock options 88 20

Proceeds from stock options exercised - 12

Purchase of treasury stock

(subsequently retired) (10,603) -

Net cash used in financing activities (10,754) (1,813)

Effect of exchange rate changes

on cash and cash equivalents (2,482) 1,763

Net increase (decrease) in

cash and cash equivalents 6,039 (39,809)

Cash and cash equivalents

at beginning of the period 92,902 89,805

Cash and cash equivalents

at end of the period $98,941 $49,996

and other brands, increased $12 million or 5% to $259 million from $247 million for the prior like quarter. Gross profit for the Wholesale operation increased to 44%, compared with 40% for the prior like quarter, reflecting greater efficiencies in supply chain management. The Company is currently experiencing higher purchase prices of certain raw materials. It is anticipated that a portion of these cost increases will be reflected in the prices of the Company's products.

The Wholesale/US Nutrition division utilizes valuable consumer preference sales data generated by the Company's Vitamin World retail stores and Puritan's Pride Direct Response/E-Commerce operations to empower its wholesale customers with this latest data. The Vitamin World stores are used as a laboratory for new ideas and are an effective tool in determining and monitoring consumer preferences. This information, as well as scanned sales data from the Vitamin World stores, is shared on a real time basis with our wholesale customers to give them a competitive advantage.

Net sales for the North American Retail division increased $1 million, or 2% to $56 million for the fiscal first quarter ended December 31, 2007 compared with $55 million for the prior like quarter. While Adjusted EBITDA was positive, this division operated at an approximate $1 million loss.

Same store sales for North American Retail increased 6% for the fiscal first quarter of 2008. The North American Retail division continues to focus on rationalizing SKU's, enhancing visual merchandising and increasing customer traffic. During the fiscal first quarter of 2008, the North American Retail division closed 5 under-performing stores and added 2 new stores. At the end of the fiscal first quarter, the North American Retail division operated a total of 534 stores consisting of 454 Vitamin World stores in the United States and 80 LeNaturiste stores in Canada. During the remainder of fiscal 2008, Vitamin World anticipates closing approximately 18 under-performing stores and opening approximately 10 stores.

European Retail net sales for the fiscal first quarter of 2008 increased $6 million, or 4% to $159 million from $153 million for the prior like period. European Retail division same store sales in local currency decreased 4%. The European Retail division continues to leverage its premier status, high street locations and brand awareness in a difficult retail environment. The European Retail division consists of 514 Holland & Barrett and 31 GNC stores in the UK, 19 Nature's Way stores in Ireland, and 70 DeTuinen stores in the Netherlands for a total of 634 stores. During the fiscal first quarter of 2008 the European Retail division opened 8 stores.

Net sales from Direct Response/E-Commerce operations for the fiscal first quarter of 2008 decreased $14 million, or 28% to $37 million from $52 million for the fiscal first quarter of 2007. This division varies its promotional strategy throughout the fiscal year. In the fiscal first quarter 2007, Direct Response utilized a highly promotional priced catalog which was not offered in the currently reported quarter. Therefore, in this less promotional quarter, Direct Response realized lower results. Direct Response's historical results reflect this pattern and should therefore be viewed on an annual and not quarterly basis.

The Direct Response operations include catalog and online internet sales. This Division's strategic plan is to increase internet sales by continuing to incorporate new technologies. For this fiscal first quarter online sales increased to 40% of total Direct Response/E-Commerce sales compared to 36% for the fiscal first quarter of 2007. NBTY remains the leader in the direct response and e-commerce sectors and continues to increase the number of products available via its catalog and web sites.

NBTY Chairman and CEO, Scott Rudolph, said: "NBTY maintained its leadership position. We are confident that the initiatives we instituted in our direct response business will be the cornerstone for generating positive results. We continue to enhance our position as the global leader in the nutritional supplement industry and take steps to best respond to cyclical changes in industry segments and garner greater market share."


NBTY is a leading global vertically integrated manufacturer, marketer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. Under a number of NBTY and third party brands, the Company offers over 22,000 products, including products marketed by the Company's Nature's Bounty(R) (, Vitamin World(R) (, Puritan's Pride(R) (, Holland & Barrett(R) (, Rexall(R) (, Sundown(R) (, MET-Rx(R) (, WORLDWIDE Sport Nutrition(R) (, American Health(R) (, GNC (UK)(R) (, DeTuinen(R) (, LeNaturiste(TM) (, SISU(R) (, Solgar(R) ( and Ester-C(R) ( brands.

This release refers to non-GAAP financial measures, such as Adjusted EBITDA. "Adjusted EBITDA" is defined as net income, excluding the aggregate amount of all non-cash losses reducing net income, plus interest, taxes, depreciation and amortization. This non-GAAP financial measure is not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. A reconciliation of the non-GAAP measure to the comparable GAAP measure is included in the attached financial tables. Management believes the presentation of Adjusted EBITDA is relevant and useful because Adjusted EBITDA is a measurement industry analysts utilize when evaluating NBTY's operating performance. Management also believes Adjusted EBITDA enhances an investor's understanding of NBTY's results of operations because it measures NBTY's operating performance exclusive of interest and non-cash charges for depreciation and amortization. Management also provides this non-GAAP measurement as a way to help investors better understand its core operating performance, enhance comparisons of NBTY's core operating performance from period to period and to allow better comparisons of NBTY's operating performance to that of its competitors.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terminology such as "subject to," "believe," "expects," "plan," "project," "estimate," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although all of these forward looking statements are believed to be reasonable, they are inherently uncertain. Factors which may materially affect such forward-looking statements include: (i) slow or negative growth in the nutritional supplement industry; (ii) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest or disruption of mail service; (iii) adverse publicity regarding nutritional supplements; (iv) inability to retain customers of companies (or mailing lists) recently acquired; (v) increased competition; (vi) increased costs; (vii) loss or retirement of key members of management; (viii) increases in the cost of borrowings and/or unavailability of additional debt or equity capital; (ix) unavailability of, or inability to consummate, advantageous acquisitions in the future, including those that may be subject to bankruptcy approval or the inability of NBTY to integrate acquisitions into the mainstream of its business; (x) changes in general worldwide economic and political conditions in the markets in which NBTY may compete from time to time; (xi) the inability of NBTY to gain and/or hold market share of its wholesale and/or retail customers anywhere in the world; (xii) unavailability of electricity in certain geographical areas; (xiii) the inability of NBTY to obtain and/or renew insurance and/or the costs of the same; (xiv) exposure to and expense of defending and resolving product liability and intellectual property claims and other litigation; (xv) the ability of NBTY to successfully implement its business strategy; (xvi) the inability of NBTY to manage its retail, wholesale, manufacturing and other operations efficiently; (xvii) consumer acceptance of NBTY's products; (xviii) the inability of NBTY to renew leases for its retail locations; (xix) the inability of NBTY's retail stores to attain or maintain profitability; (xx) the absence of clinical trials for many of NBTY's products; (xxi) sales and earnings volatility and/or trends for the Company and its market segments; (xxii) the efficacy of NBTY's Internet and on-line sales and marketing strategies; (xxiii) fluctuations in foreign currencies, including the British Pound, the Euro and the Canadian dollar; (xxiv) import-export controls on sales to foreign countries; (xxv) the inability of NBTY to secure favorable new sites for, and delays in opening, new retail and manufacturing locations; (xxvi) introduction of and compliance with new federal, state, local or foreign legislation or regulation or adverse determinations by regulators anywhere in the world (including the banning of products) and more particularly Good Manufacturing Practices in the United States, the Food Supplements Directive and Traditional Herbal Medicinal Products Directive in Europe and Section 404 requirements of the Sarbanes-Oxley Act of 2002; (xxvii) the mix of NBTY's products and the profit margins thereon; (xxviii) the availability and pricing of raw materials; (xxix) risk factors discussed in NBTY's filings with the U.S. Securities and Exchange Commission; (xxx) adverse effects on NBTY as a result of increased energy prices and potentially reduced traffic flow to NBTY's retail locations; (xxxi) adverse tax determinations; (xxxii) the loss of a significant customer of the Company; (xxxiii) potential investment losses as a result of liquidity conditions; and (xxxiv) other factors beyond the Company's control.

Readers are cautioned not to place undue reliance on forward-looking statements. NBTY cannot guarantee future results, trends, events, levels of activity, performance or achievements. NBTY does not undertake and specifically declines any obligation to update, republish or revise forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events.

Consequently, such forward-looking statements should be regarded solely as NBTY's current plans, estimates and beliefs.

Contact: Harvey Kamil Carl Hymans

NBTY, Inc. G.S. Schwartz & Co.

President and Chief Financial Officer 212-725-4500


NBTY, Inc. and Subsidiaries

Condensed Consolidated Statements of Income


(In thousands, except per share amounts)

For the three months

ended December 31,

2007 2006

Net sales $510,858 $ 506,237

Costs and expenses:

Cost of sales 240,331 247,047

Advertising, promotion and catalog 34,169 26,763

Selling, general and administrative 168,123 151,939

442,623 425,749

Income from operations 68,235 80,488

Other income (expense):

Interest (3,862) (5,063)

Miscellaneous, net 4,887 1,339

1,025 (3,724)

Income before provision for income taxes 69,260 76,764

Provision for income taxes 23,438 25,908

Net income $45,822 $50,856

Net income per share:

Basic $0.68 $0.76

Diluted $0.67 $0.73

Weighted average common shares outstanding:

Basic 66,903 67,213

Diluted 68,786 69,331






(In thousands) 2007 2006 Change

Wholesale / US Nutrition $258,935 $246,728 5%

North American Retail 56,182 54,973 2%

European Retail 158,597 152,966 4%

Direct Response / E-Commerce 37,144 51,570 -28%

Total $510,858 $506,237 1%







2007 2006 - Decrease

Wholesale / US Nutrition 44% 40% 4%

North American Retail 59% 60% -1%

European Retail 63% 63% 0%

Direct Response / E-Commerce 63% 62% 1%

Total 53% 51% 2%


Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Moog Reports 14% Increase in Earnings Per Share
2. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
3. WellPoint Reports Fourth Quarter and Full Year 2007 Results
4. Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance
5. TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations
6. Health care reform and 2008 elections: New reports examine candidates plans, publics views
7. Consumer Reports Health News
8. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
9. FDA Reports New Risks Posed by Anemia Drugs
10. Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement
11. UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... Dec. 1, 2015 Express Scripts (NASDAQ: ESRX ... IMMY ) to drive access to a low-cost alternative ... of toxoplasmosis that has been recently priced out of reach ... immune systems. --> --> ... leucovorin (a form of folic acid) for $1 per capsule for ...
Breaking Medicine Technology: